BlackRock Fund Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

BlackRock Fund Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$18.5M	Buy	2,666,777 +418,298	+19%	+$2.88M	﹤0.01%	2225
2016 Q3	$18.5M	Buy	2,248,479 +441,276	+24%	+$3.73M	﹤0.01%	2115
2016 Q2	$14.6M	Buy	1,807,203 +22,544	+1%	+$142K	﹤0.01%	2201
2016 Q1	$9.07M	Sell	1,784,659 -5,672	-0.3%	-$31K	﹤0.01%	2417
2015 Q4	$13.8M	Buy	1,790,331 +605,664	+51%	+$4.2M	﹤0.01%	2261
2015 Q3	$6.82M	Buy	1,184,667 +246	+0%	+$1.92K	﹤0.01%	2602
2015 Q2	$10.9M	Buy	+1,184,421	New	+$13.2M	﹤0.01%	2450

Other funds holding IOVA

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BlackRock Fund Advisors's IOVA Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Iovance Biotherapeutics (IOVA) stake by 19% in Q4 2016, buying an estimated $2.88M and bringing the position to 2,666,777 shares worth $18.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2225.

BlackRock Fund Advisors first reported a position in IOVA in Q2 2015 and has held it in 7 quarters since. 87 funds tracked by Wall St. Rank hold IOVA as of Q4 2016.

BlackRock Fund Advisors held 2,666,777 shares of Iovance Biotherapeutics worth $18.5M as of Q4 2016.
BlackRock Fund Advisors bought 418,298 Iovance Biotherapeutics shares in Q4 2016, an estimated $2.88M.
Iovance Biotherapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2225 holding.
BlackRock Fund Advisors first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 7 quarters since.
87 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.